The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Calidi Biotherapeutics Inc shares valued at $1,237 were sold by Camaisa Allan on Dec 12 ’25. At $1.46 per share, Camaisa Allan sold 850 shares. The insider’s holdings dropped to 76,952 shares worth approximately $90033.84 following the completion of this transaction.
Also, Schoeneck James A purchased 75,000 shares, netting a total of over 150,000 in proceeds. Following the buying of shares at $2.00 each, the insider now holds 76,134 shares.
Before that, Poma Eric E had added 25,000 shares to its account. In a trade valued at $50,000, the Chief Executive Officer bought Calidi Biotherapeutics Inc shares for $2.00 each. Upon closing the transaction, the insider’s holdings increased to 25,000 shares, worth approximately $29250.0.
As published in their initiating research note from H.C. Wainwright on November 22, 2023, Calidi Biotherapeutics Inc [CLDI] has been a Buy and the price target has been revised to $11. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in early October.
Analyzing CLDI Stock Performance
On last trading session, Calidi Biotherapeutics Inc [AMEX: CLDI] rose 1.74% to $1.17. The stock’s lowest price that day was $1.1203, but it reached a high of $1.2125 in the same session. During the last five days, there has been a drop of approximately -10.00%. Over the course of the year, Calidi Biotherapeutics Inc shares have dropped approximately -92.72%. Shares of the company reached a 52-week high of $19.2000 on 07/09/25 and a 52-week low of $1.1000 on 11/07/25.
Support And Resistance Levels for Calidi Biotherapeutics Inc (CLDI)
According to the 24-hour chart, there is a support level at 1.1227, which, if violated, would cause prices to drop to 1.0754. In the upper region, resistance lies at 1.2149. The next price resistance is at 1.2598. RSI (Relative Strength Index) is 34.58 on the 14-day chart, showing neutral technical sentiment.
Is Calidi Biotherapeutics Inc subject to short interest?
Stocks of Calidi Biotherapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by 98995.0 shares to 71326.0. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 0.17 million shares. A decline of -138.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.87 of the overall float, the days-to-cover ratio (short ratio) decline to 0.87.
Which companies own the most shares of Calidi Biotherapeutics Inc (CLDI)?
In terms of Calidi Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5.5 in the next 12 months, up nearly 378.26% from the previous closing price of $1.15. Analysts anticipate Calidi Biotherapeutics Inc stock to reach 9 by 2026, with the lowest price target being 2.
